tradingkey.logo

PAVmed Inc

PAVM
0.357USD
-0.019-5.18%
Market hours ETQuotes delayed by 15 min
7.18MMarket Cap
0.10P/E TTM

PAVmed Inc

0.357
-0.019-5.18%
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison

TradingKey Stock Score of PAVmed Inc

Currency: USD Updated: 2025-11-04

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company shows very weak stock market performance, in line with its fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

PAVmed Inc's Score

Industry at a Glance

Industry Ranking
145 / 210
Overall Ranking
349 / 4616
Industry
Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 2 analysts
Buy
Current Rating
12.000
Target Price
+2900.00%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

PAVmed Inc Highlights

StrengthsRisks
PAVmed Inc. is a multi-product, commercial-stage medical technology company. The Company operates through three lines of business: Medical Devices, Diagnostics, and Digital Health. Its subsidiary includes Lucid Diagnostics Inc., which is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device for early detection of esophageal precancer to prevent esophageal cancer deaths. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells. EsoGuard is a bisulfite-converted next-generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. Its other subsidiary, Veris Health Inc., is focused on enhanced personalized cancer care through remote patient monitoring using implantable vascular access port with wireless communication combined with an oncologist-designed remote digital healthcare platform.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 694.43% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 3.00M.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Fairly Valued
The company’s latest PE is 0.05, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 2.26M shares, increasing 16.26% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 81.49K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.27.

Financial Health

Currency: USD Updated: 2025-11-04

The company's current financial score is 5.29, which is lower than the Healthcare Equipment & Supplies industry's average of 7.46. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 6.00K, representing a year-over-year decrease of 99.39%, while its net profit experienced a year-over-year decrease of 22.00%.

Score

Industry at a Glance

Previous score
5.29
Change
0

Financials

6.10

Key Metrics

Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
No Data

Quality of Earnings

6.50

Operational Efficiency

2.57

Growth Potential

4.18

Shareholder Returns

7.11

PAVmed Inc's Company Valuation

Currency: USD Updated: 2025-11-04

The company’s current valuation score is 6.76, which is lower than the Healthcare Equipment & Supplies industry's average of 7.19. Its current P/E ratio is 0.05, which is 1811.74% below the recent high of 0.98 and 2149.51% above the recent low of -1.05.

Score

Industry at a Glance

Previous score
6.76
Change
0

Valuation Dimensions

P/E
P/B
P/S
P/CF
Industry Ranking 145/210
No Data

Earnings Forecast

Currency: USD Updated: 2025-11-04

The company’s current earnings forecast score is 8.00, which is higher than the Healthcare Equipment & Supplies industry's average of 7.74. The average price target for PAVmed Inc is 12.00, with a high of 20.00 and a low of 4.00.

Score

Industry at a Glance

Previous score
8.00
Change
0

Support & Resistance

No Data

Analyst Rating

Based on 2 analysts
Buy
Current Rating
12.000
Target Price
+2900.00%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

89
Total
4
Median
7
Average
Company name
Ratings
Analysts
PAVmed Inc
PAVM
2
Boston Scientific Corp
BSX
37
Intuitive Surgical Inc
ISRG
35
Edwards Lifesciences Corp
EW
35
Veeva Systems Inc
VEEV
34
Thermo Fisher Scientific Inc
TMO
28
1
2
3
...
18

Financial Forecasting

EPS
Revenue
Net Profit
EBIT
No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-04

The company’s current price momentum score is 4.19, which is lower than the Healthcare Equipment & Supplies industry's average of 6.77. Sideways: Currently, the stock price is trading between the resistance level at 0.53 and the support level at 0.30, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score
4.04
Change
0.15

Support & Resistance

No Data

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(3)
Neutral(1)
Buy(0)
Indicators
Value
Direction
MACD(12,26,9)
-0.020
Sell
RSI(14)
35.169
Neutral
STOCH(KDJ)(9,3,3)
14.379
Oversold
ATR(14)
0.043
Low Volatility
CCI(14)
-138.609
Sell
Williams %R
96.525
Oversold
TRIX(12,20)
-0.357
Sell
StochRSI(14)
0.000
Oversold
Moving Average
Sell(6)
Neutral(0)
Buy(0)
Indicators
Value
Direction
MA5
0.413
Sell
MA10
0.422
Sell
MA20
0.464
Sell
MA50
0.451
Sell
MA100
0.500
Sell
MA200
0.596
Sell

Institutional Confidence

Currency: USD Updated: 2025-11-04

The company’s current institutional recognition score is 3.00, which is lower than the Healthcare Equipment & Supplies industry's average of 6.39. The latest institutional shareholding proportion is 10.64%, representing a quarter-over-quarter decrease of 63.62%. The largest institutional shareholder is The Vanguard, holding a total of 81.49K shares, representing 0.29% of shares outstanding, with 58.96% decrease in holdings.

Score

Industry at a Glance

Previous score
3.00
Change
0

Institutional Shareholding

No Data

Shareholder Activity

Name
Shares Held
Chg %
Tasso Partners, LLC
2.57M
--
Sargent Investment Group, LLC
1.01M
--
First Manhattan Co. LLC
714.10K
--
Dubreville (Anthony Michael)
606.26K
--
Pavilion Venture Partners, L.L.C.
297.11K
--
Aklog (Lishan)
228.72K
+190.54%
Glennon (Michael J)
231.67K
+183.67%
White (Debra Jayne)
215.00K
+230.77%
Sparks (Ronald M)
215.00K
+230.77%
Baxter (Timothy E)
215.00K
+230.77%
1
2

Risk Assessment

Currency: USD Updated: 2025-11-04

The company’s current risk assessment score is 2.07, which is lower than the Healthcare Equipment & Supplies industry's average of 4.57. The company's beta value is 1.09. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.

Score

Industry at a Glance

Previous score
2.07
Change
0
Beta vs S&P 500 index
1.09
VaR
+9.09%
240-Day Maximum Drawdown
+68.12%
240-Day Volatility
+112.19%

Return

Best Daily Return
60 days
+13.67%
120 days
+13.67%
5 years
+43.70%
Worst Daily Return
60 days
-9.60%
120 days
-13.72%
5 years
-30.81%
Sharpe Ratio
60 days
-0.73
120 days
-1.62
5 years
-0.36

Risk Assessment

Maximum Drawdown
240 days
+68.12%
3 years
+95.39%
5 years
+99.69%
Return-to-Drawdown Ratio
240 days
-0.93
3 years
-0.33
5 years
-0.20
Skewness
240 days
+0.73
3 years
+1.12
5 years
+0.87

Volatility

Realised Volatility
240 days
+112.19%
5 years
+117.91%
Standardised True Range
240 days
+15.45%
5 years
+424.74%
Downside Risk-Adjusted Return
120 days
-247.85%
240 days
-247.85%
Maximum Daily Upside Volatility
60 days
+70.40%
Maximum Daily Downside Volatility
60 days
+60.46%

Liquidity

Average Turnover Rate
60 days
+1.16%
120 days
+1.12%
5 years
--
Turnover Deviation
20 days
+27.23%
60 days
-22.17%
120 days
-25.07%

Peer Comparison

Healthcare Equipment & Supplies
PAVmed Inc
PAVmed Inc
PAVM
5.28 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Castle Biosciences Inc
Castle Biosciences Inc
CSTL
8.67 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Cencora Inc
Cencora Inc
COR
8.60 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
AxoGen Inc
AxoGen Inc
AXGN
8.58 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
TCMD
8.57 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Zimmer Biomet Holdings Inc
Zimmer Biomet Holdings Inc
ZBH
8.54 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
KeyAI